CSF3 and neutropenia: In conclusion, our data suggest that the use of pegfilgrastim compared with a daily G-CSF, and primary prophylaxis compared with secondary prophylaxis could decrease the incidence of neutropenia and its related events in patients with solid tumours undergoing chemotherapy.